Telo Genomics appoints Farlinger as CEO, chairman

Executive Summary

• Telo Genomics Corp. has appointed John Farlinger as Chief Executive Officer and Chairman, succeeding Dr. Sabine Mai, who remains as a director.
• The appointment is accompanied by a significant stock option grant to Mr. Farlinger and the engagement of an investor relations firm, Sheridan Adams LLC.
• Mr. Farlinger outlined strategic milestones, including expected clinical study results by summer 2026, an FDA application filing, and a goal for Medicare reimbursement approval in 2027.

Key Details

• CEO Appointment: John Farlinger appointed as CEO and Chairman; succeeds Dr. Sabine Mai (Founder), who continues as a director.
• Management Agreement: Mr. Farlinger entered into a management consulting agreement in connection with his appointment.
• Option Grant to CEO:
  • Quantity: 3.7 million stock options.
  • Effective Date: March 18, 2026.
  • Exercise Price: 5.5 cents per share.
  • Vesting: 50% vests immediately upon grant; balance vests per the employee stock option plan.
  • Expiration: Five years after grant date.
  • Hold Period: Four-month hold period per TSX Venture Exchange policies.
• Investor Relations Engagement:
  • Firm: Sheridan Adams LLC engaged for financial and corporate investor/public relations services.
  • Effective Date: March 1, 2026.
  • Services: Capital-raising support, increasing trading volume, institutional investor contact, sell-side analyst coverage, and conference participation.
  • Fee: $4,000 (U.S.) monthly cash fee for an initial six-month term, with automatic renewal.
  • Termination: Either party may terminate with 30 days' written notice.
• Option Grant to IR Firm:
  • Quantity: 250,000 options granted to Sheridan Adams LLC.
  • Effective Date: March 1, 2026.
  • Exercise Price: 5 cents per share.
  • Vesting: 36 months after grant date.
  • Expiration: Five years after grant date.
  • Hold Period: Four-month hold period per TSX Venture Exchange policies.
• Director Resignation: Guido Baechler resigned as Executive Chairman and Director, effective March 31, 2026; he will remain as an adviser.
• Strategic Outlook (CEO Quote):
  • Clinical study results testing efficacy in head-to-head trials with market leaders expected by summer 2026.
  • Work beginning to file a significant application with the U.S. FDA.
  • Goal to facilitate Medicare reimbursement approval in 2027.
  • Focus on commercializing tests for precision oncology, specifically for multiple myeloma.

Notable Quotes

• "I am excited to play a leading role in shaping Telo Genomics' strategy at this pivotal point in the company's development," said Mr. Farlinger. "By the summer of 2026, Telo Genomics expects to report clinical study results that will test the efficacy of our technology in head-to-head trials with market leaders. In parallel path, we are beginning the work necessary to file a significant application with the U.S. FDA [Food and Drug Administration], and our goal is to facilitate Medicare reimbursement approval in 2027."
• "Together with the recent appointment of John Price as chief financial officer, Telo Genomics is now led by a management team skilled in public company strategic leadership and successfully financing small-cap growth companies. We are entirely focused on developing, commercializing and monetizing the company's telomere technology platform."